PH12015501002A1 - Treatment of cancer with pomalidomide in a renally impaired subject - Google Patents
Treatment of cancer with pomalidomide in a renally impaired subjectInfo
- Publication number
- PH12015501002A1 PH12015501002A1 PH12015501002A PH12015501002A PH12015501002A1 PH 12015501002 A1 PH12015501002 A1 PH 12015501002A1 PH 12015501002 A PH12015501002 A PH 12015501002A PH 12015501002 A PH12015501002 A PH 12015501002A PH 12015501002 A1 PH12015501002 A1 PH 12015501002A1
- Authority
- PH
- Philippines
- Prior art keywords
- pomalidomide
- cancer
- subject
- treatment
- impaired subject
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 title abstract 3
- 229960000688 pomalidomide Drugs 0.000 title abstract 3
- 230000001771 impaired effect Effects 0.000 title 1
- 206010062237 Renal impairment Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 abstract 1
- 229960003957 dexamethasone Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261722722P | 2012-11-05 | 2012-11-05 | |
| US201361764466P | 2013-02-13 | 2013-02-13 | |
| PCT/US2013/068237 WO2014071280A1 (en) | 2012-11-05 | 2013-11-04 | Treatment of cancer with pomalidomide in a renally impaired subject |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12015501002A1 true PH12015501002A1 (en) | 2015-07-27 |
Family
ID=50628132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12015501002A PH12015501002A1 (en) | 2012-11-05 | 2015-05-05 | Treatment of cancer with pomalidomide in a renally impaired subject |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20150297579A1 (enExample) |
| EP (1) | EP2914112A4 (enExample) |
| JP (1) | JP2015535291A (enExample) |
| CN (1) | CN104902754A (enExample) |
| AU (1) | AU2013337352A1 (enExample) |
| BR (1) | BR112015010039A2 (enExample) |
| CA (1) | CA2889987A1 (enExample) |
| EA (1) | EA201590883A1 (enExample) |
| HK (1) | HK1214552A1 (enExample) |
| IL (1) | IL238563A0 (enExample) |
| MX (1) | MX2015005548A (enExample) |
| NI (1) | NI201500063A (enExample) |
| PH (1) | PH12015501002A1 (enExample) |
| SG (1) | SG11201503456TA (enExample) |
| WO (1) | WO2014071280A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201507759WA (en) * | 2013-04-02 | 2015-10-29 | Celgene Corp | Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers |
| WO2019051125A1 (en) | 2017-09-06 | 2019-03-14 | Translational Drug Development, Llc | AMINOBENZIMIDAZOLE DERIVATIVES, TREATMENTS AND METHODS FOR INHIBITING HISTONE DEACETYLASE |
| EP3297674B1 (en) * | 2015-05-22 | 2023-01-04 | Translational Drug Development Llc | Benzamide and active compound compositions and methods of use |
| CN105456232A (zh) * | 2015-09-08 | 2016-04-06 | 刘剑 | 一种泊马度胺速溶膜剂及其制备方法 |
| AU2016394945A1 (en) * | 2016-03-02 | 2018-10-11 | Translational Drug Development Llc | Aminobenzimidazole derivatives |
| WO2018013689A1 (en) * | 2016-07-13 | 2018-01-18 | Celgene Corporation | Solid dispersions and solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, method of preparation and use thereof |
| CN108721304B (zh) * | 2017-04-17 | 2020-10-16 | 北京大学 | 用于治疗肿瘤的药物组合物及其用途 |
| AR119715A1 (es) | 2019-04-12 | 2022-01-05 | Celgene Corp | Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona |
| GB202012160D0 (en) * | 2020-08-05 | 2020-09-16 | Vicore Pharma Ab | New compositions |
| EP4479082A2 (en) * | 2022-02-15 | 2024-12-25 | The Broad Institute, Inc. | Cell-type specific targeting contractile injection system |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| JP5339588B2 (ja) * | 2008-11-10 | 2013-11-13 | 国立大学法人 新潟大学 | サリドマイドまたはその誘導体を有効成分とする統合失調症の治療薬 |
| JP5553275B2 (ja) * | 2010-03-31 | 2014-07-16 | 国立大学法人金沢大学 | 金属錯体およびこれを有効成分として含有する抗がん剤 |
| JP2014517915A (ja) * | 2011-04-18 | 2014-07-24 | セルジーン コーポレイション | 多発性骨髄腫治療のためのバイオマーカー |
| EP3096142A3 (en) * | 2011-04-29 | 2017-03-08 | Celgene Corporation | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
-
2013
- 2013-11-04 US US14/440,333 patent/US20150297579A1/en not_active Abandoned
- 2013-11-04 AU AU2013337352A patent/AU2013337352A1/en not_active Abandoned
- 2013-11-04 MX MX2015005548A patent/MX2015005548A/es unknown
- 2013-11-04 EP EP13850977.3A patent/EP2914112A4/en not_active Withdrawn
- 2013-11-04 CA CA2889987A patent/CA2889987A1/en not_active Abandoned
- 2013-11-04 EA EA201590883A patent/EA201590883A1/ru unknown
- 2013-11-04 BR BR112015010039A patent/BR112015010039A2/pt not_active IP Right Cessation
- 2013-11-04 JP JP2015540844A patent/JP2015535291A/ja active Pending
- 2013-11-04 CN CN201380069405.4A patent/CN104902754A/zh active Pending
- 2013-11-04 HK HK16102558.2A patent/HK1214552A1/zh unknown
- 2013-11-04 SG SG11201503456TA patent/SG11201503456TA/en unknown
- 2013-11-04 WO PCT/US2013/068237 patent/WO2014071280A1/en not_active Ceased
-
2015
- 2015-04-30 IL IL238563A patent/IL238563A0/en unknown
- 2015-05-04 NI NI201500063A patent/NI201500063A/es unknown
- 2015-05-05 PH PH12015501002A patent/PH12015501002A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1214552A1 (zh) | 2016-07-29 |
| SG11201503456TA (en) | 2015-05-28 |
| WO2014071280A1 (en) | 2014-05-08 |
| JP2015535291A (ja) | 2015-12-10 |
| EA201590883A1 (ru) | 2015-09-30 |
| BR112015010039A2 (pt) | 2017-07-11 |
| US20150297579A1 (en) | 2015-10-22 |
| CA2889987A1 (en) | 2014-05-08 |
| EP2914112A4 (en) | 2016-06-15 |
| AU2013337352A1 (en) | 2015-05-21 |
| CN104902754A (zh) | 2015-09-09 |
| IL238563A0 (en) | 2015-06-30 |
| NI201500063A (es) | 2015-09-10 |
| MX2015005548A (es) | 2016-01-15 |
| EP2914112A1 (en) | 2015-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015501002A1 (en) | Treatment of cancer with pomalidomide in a renally impaired subject | |
| PH12015500246A1 (en) | Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor | |
| MX2015013166A (es) | Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17. | |
| UA117451C2 (uk) | Терапевтично активні сполуки і способи їх застосування | |
| AU2011328009A8 (en) | Compounds and methods for treating pain | |
| MX2020011772A (es) | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. | |
| MX2021000538A (es) | Uso de sobetirome en el tratamiento de enfermedades de mielinizacion. | |
| PH12014501736B1 (en) | Therapeutic use of p75ntr neurotrophin binding protein | |
| PH12015502042A1 (en) | Use of linagliptin in cardio-and renoprotective antidiabetic therapy | |
| NZ707477A (en) | Activin-actrii antagonists and uses for treating bone and other disorders | |
| MX2015012922A (es) | Tratamiento del cancer usando anticuerpos que se unen a grp78 en la superficie celular. | |
| PH12016500164B1 (en) | Therapeutically active compounds and their methods of use | |
| EA201390506A1 (ru) | Полипептиды, которые связывают компонент с5 комплемента человека | |
| TW201613636A (en) | Methods of treating Alzheimer's Disease | |
| MX2015012322A (es) | Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes. | |
| PH12015500169A1 (en) | Prediction of treatment response to jak/stat inhibitor | |
| MX2015011905A (es) | Uso de levocetirizina y montelukast en el tratamiento de la vasculitis. | |
| JP2015535291A5 (enExample) | ||
| WO2014153385A3 (en) | Methods of treating metabolic disorders | |
| MX2019000677A (es) | Células miméticas de células b. | |
| EA201500363A1 (ru) | Человеческие анти-vegfr-2/kdr-антитела | |
| IN2012DN02195A (enExample) | ||
| MX2011008994A (es) | Metodos de usar sns - 595 para el tratamiento de sujetos con cancer con actividad reducida de brca2. | |
| UA84189U (ru) | Способ лечения больных гастроэзофагеальной рефлюксной болезнью на фоне хронического обструктивного заболевания легких | |
| TR201819348T4 (tr) | Otizm Bozukluklarının Mentol, Linalool ve/veya İsilin İle Tedavisi ya da Önlenmesi |